BioMarCare
Tumor Biomarker Technologies for Early Cancer Diagnosis
Company Overview
Snapshot
Founded in January 2002, BioMarCare operated with 1–10 employees, focusing on early cancer diagnosis through tumor biomarker technologies. The company raised $1.9 million across three funding rounds from two investors.
Business overview
BioMarCare specializes in developing multi-biomarker panel approaches to create molecular blood tests and tissue-based diagnostic (IHC) tests for early cancer diagnosis. Their core products include Colon-MarCarePlex, a colorectal cancer screening test measuring gene expression biomarkers, and MCRC-Strat, a semi-quantitative IHC assay designed to predict patient responses to epidermal growth factor receptor-targeting drugs. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics, serving laboratories within the broader healthcare market.
Strategic signal
In September 2019, BioMarCare was highlighted in a market development scenario report for colorectal cancer diagnostics, positioning its Colon-MarCarePlex product within a competitive landscape alongside major industry players. This signals the company's established presence and relevance in the diagnostic market, indicating its technology was considered a notable contributor to early cancer detection solutions prior to its cessation of operations.
Company Intelligence Q&A
- What is BioMarCare's primary focus?
- BioMarCare focuses on developing tumor biomarker technologies for the early diagnosis of cancer, utilizing multi-biomarker panel approaches for molecular blood tests and tissue-based diagnostic tests.
- When was BioMarCare founded?
- BioMarCare was founded in January 2002.
- What is Colon-MarCarePlex?
- Colon-MarCarePlex is an accurate, patient-friendly colorectal cancer screening test developed by BioMarCare. It measures the expression of several genes as biomarkers to detect advanced adenoma polyps and early-stage colorectal cancer.
- What is MCRC-Strat?
- MCRC-Strat is a semi-quantitative IHC assay developed by BioMarCare that uses a protein biomarker combination to predict patient responses to drugs targeting the epidermal growth factor receptor. This product was being developed in collaboration with a U.S. partner.
- What was the company's operational status in August 2020?
- BioMarCare ceased to operate in August 2020.